Wilex: FDA offers adcomm for Redectane

Wilex AG (Xetra:WL6) said it accepted an offer from FDA to participate in an advisory committee meeting to discuss the development and regulatory pathway of kidney cancer diagnostic Redectane. Wilex said FDA made the offer at a meeting with the company to discuss next steps for Redectane. FDA is expected to confirm the meeting after internal verification of logistics, according to Wilex. Wilex was down EUR 0.03 to EUR 4.25 on Wednesday. ...